Mixed cryoglobulinemic vasculitis—a rare disorder that is characterized by the presence of abnormal proteins in the blood that become insoluble at low temperatures and restrict blood flow—may be successfully managed with the use of rituximab as a generally well tolerated, glucocorticoid-sparing therapy.
Mixed cryoglobulinemic vasculitis (MCV)—a rare disorder that is characterized by the presence of abnormal proteins in the blood that become insoluble at low temperatures and restrict blood flow—may be successfully managed with the use of rituximab as a generally well tolerated, glucocorticoid-sparing therapy.
Biosimilar rituximab, which is available in the European Union, has the potential to reduce the cost associated with rituximab therapy for this rare disease, but few data are available about biosimilar rituximab’s safety and effectiveness in patients with MCV.
An Italian study recently presented at the European League Against Rheumatism’s 2019 congress analyzed the safety of the biosimilar in patients with MCV. In the multicenter, open-label study, all patients with MCV who were treated with the biosimilar, either with the biosimilar as first-line treatment or after switching from the reference rituximab product, were included.
In total, 19 patients were treated in a 6-month period in 2018. Nine of them were treated with the biosimilar only, while 10 switched from the reference.
In the month following the patients’ final infusions, 5 adverse events (AEs) were observed: 2 vasculitis flares, and 1 case each of urticaria, atrial fibrillation, and septicemia. Three of the 5 AEs occurred in patients receiving high doses of rituximab.
There were no differences observed in AEs between the treatment-naïve patients and those switched from the reference.
Despite the low number of patients included in the study, write the authors, switching to the biosimilar appeared to be safe, and AEs were in line with the known safety profile of rituximab in MCV.
Reference
Vacchi C, Visentini M, Cicco MD, et al. Safety of rituximab biosimilar for the treatment of cryoglobulinemic vasculitis. Presented at: The European League Against Rheumatism European Congress of Rheumatology 2019; June 12-15, 2019; Madrid, Spain. Abstract AB0624.
Eye on Pharma: Bevacizumab Update; Samsung Bioepis, J&J Settlement; Another EU Trastuzumab
December 6th 2023Outlook Therapeutics provides an update on the development of its bevacizumab candidate for age-related macular degeneration; Samsung Bioepis settles with Johnson & Johnson (J&J) over its ustekinumab biosimilar candidate; and the European Union gains another trastuzumab biosimilar.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Adalimumab Biosimilars Take Center Stage: A Game Changer for IBD Treatment
July 16th 2023Laura Wingate, from the Crohn's & Colitis Foundation, explains some of the challenges regarding educating patients and providers on biosimilars for inflammatory bowel disease (IBD) as well as whether the gastroenterology space is ready for the influx of adalimumab biosimilars.
Public Payer in Poland Saves €243 Million by Using Biosimilar TNF Inhibitors
November 11th 2023The use of biosimilars of tumor necrosis factor (TNF) inhibitors within Poland’s public payer saved over €243 million from 2013 to 2021, with about 68% of that coming from the rheumatic musculoskeletal diseases alone.
Real-World Data Confirm Safety, Efficacy of CT-P13 in Inflammatory Diseases
November 9th 2023A real-world analysis from Japan confirmed that CT-P13, an intravenous infliximab biosimilar, had comparable safety and efficacy to the reference product (Remicade; infliximab) in patients with immune-mediated inflammatory diseases.